Capricor Therapeutics Stock Surges 10.5% on Duchenne Data
Capricor Therapeutics (CAPR) shares climbed 10.5% after investors focused on two-year follow-up data for its Duchenne muscular dystrophy therapy, deramiocel, presented at the World Muscle Society congress in Japan.